GRCE 8-K 2026-11-12
Grace Therapeutics, Inc. (GRCE) 8-K dated 2026-11-12 — accession 0001140361-26-043308.
Grace Therapeutics, Inc. (GRCE) is a biotechnology company listed on US.
GRCE: Grace Therapeutics Announces Second Quarter 2027 Financial Results,
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Income-statement cache for GRCE is thin on this filing URL. We will not invent exhibit numbers.
Not investment advice. The GRCE SEC hub lists recent forms. The stock page is the research view.
- Guidance
- expects,” “intends,” “anticipates,” “estimates,” “potential,” “should,” “may,” “will,” “plans,” “continue,” “targeted” or other
Why it matters
- expects,” “intends,” “anticipates,” “estimates,” “potential,” “should,” “may,” “will,” “plans,” “continue,” “targeted” or other